Medicines
Discover all available medicines and treatments
Discover all available medicines and treatments
Brand: Mirapex, Sifrol, Pramiprexol
Pramipexole is a dopamine agonist primarily used to treat Parkinson's disease and restless legs syndrome (RLS). It works by mimicking the effects of dopamine, a neurotransmitter essential for movement control and other brain functions. Belonging to the non-ergoline class of dopamine agonists, pramipexole selectively stimulates dopamine D2 and D3 receptors, particularly in the striatum, a brain region involved in motor control. It helps to alleviate symptoms such as tremors, stiffness, slow movement, and sleep disturbances associated with these conditions.
For Parkinson's disease, restless legs syndrome, and occasionally for other movement disorders.
Outcome:
Increased pramipexole levels
Mechanism:
Reduced renal clearance
Outcome:
Increased dopaminergic effects
Mechanism:
Additive dopaminergic effects
Outcome:
Slightly decreased pramipexole absorption
Mechanism:
Altered gastric pH
Most likely new formulation: Extended-release pramipexole for improved patient compliance (Year: 2025, 75% confidence)
Based on current usage trends and ongoing research, pramipexole is predicted to maintain its current FDA-approved indications for the foreseeable future with a 90% likelihood.
Dopamine Agonist, Non-Ergoline
Benzothiazole